<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156696">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059825</url>
  </required_header>
  <id_info>
    <org_study_id>8835-016</org_study_id>
    <nct_id>NCT01059825</nct_id>
  </id_info>
  <brief_title>Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)</brief_title>
  <official_title>A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational
      drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
      Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment
      with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1C (HbA1C) at Day 84</measure>
    <time_frame>Baseline and Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight at Day 84</measure>
    <time_frame>Baseline and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic and Diastolic Blood Pressure at Day 84</measure>
    <time_frame>Baseline and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose at Day 84</measure>
    <time_frame>Baseline and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1C &lt;7% and &lt;6.5%</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experienced an advere event (AE)</measure>
    <time_frame>Up to 98 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinuing study medication due to an AE</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertugliflozin</intervention_name>
    <description>Tablet(s), 1 or 2, 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 1 mg</intervention_name>
    <description>Tablet, 1 mg, once daily for 84 days</description>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 25 mg</intervention_name>
    <description>Tablet, 25 mg, once daily for 84 days</description>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg sitagliptin</intervention_name>
    <description>Tablet, 100 mg, once daily for 84 days</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Sitagliptin</intervention_name>
    <description>Tablet, 100 mg, once daily for 84 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes on stable doses of background medicines for management
             of the diabetes; aged 18-70 years; body mass index between 23-45 kg/m2

        Exclusion Criteria:

          -  Patients with type 1 diabetes, heart attack or stroke in last 6-months, uncontrolled
             blood pressure, significant kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015 Jun;17(6):591-8. doi: 10.1111/dom.12460. Epub 2015 Mar 31.</citation>
    <PMID>25754396</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>January 29, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>November 12, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <keyword>safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
